Home Latest Articles
Latest Articles
  • Junjie WANG, Qingrong CHENG, Jiaqing HAO, Cancan CUI, Peng HU, Pengfei WANG, Chaoyi LU
    World Clinical Drug. 2022, 43(3): 282-287.
    Objective

    To explore the clinical effects of aescin combined with ceftriaxone in the treatment of bacterial meningitis (BM).

    Methods

    A prospective study was conducted on 80 patients with BM admitted to Ningguo people's hospital from April 2019 to April 2021. According to the random lottery method, they were divided into observation group and control group at a ratio of 1∶1, with 40 cases in each group. The control group was treated with ceftriaxone, and the observation group was treated with aescin combined with ceftriaxone. We would compare the efficacy, time of symptom disappearance, inflammatory factors before and after treatment [procalcitonin (PCT), interleukin-6 (IL-6), C-reactive protein (CRP), soluble vascular cell adhesion molecule 1 (sVCAM-1)], oxidative stress indicators [superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), malondialdehyde (MDA)], brain edema index [aquaporin 4 (AQP4), S-100 calcium binding protein (S-100B)] and treatment the incidence of adverse reactions during the period.

    Results

    The total effective rate of the observation group was 92.50%, higher than that of the control group 75.00% (P<0.05). The observation group had less time of fever resolution, disappearance of intracranial hypertension, recovery of consciousness, and the disappearance of convulsions were shorter time than those in the control group (P<0.05). The levels of serum PCT, IL-6, CRP, sVCAM-1, AQP4, and S-100B in the observation group were lower than those of the control group (P<0.05). After treatment, the serum SOD and GSH-Px levels in the observation group were higher than those in the control group, and the MDA level was lower than that in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).

    Conclusions

    Aescin combined with ceftriaxone has a significant effect in the treatment of BM patients, which can effectively promote the improvement of symptoms, reduce inflammation and oxidative stress in the body, relieve cerebral edema with high safety.

  • Changping ZHANG, Xia WANG, Yanping TIAN, Wei LIU
    World Clinical Drug. 2022, 43(3): 288-293.
    Objective

    To investigate the effects and risk factors of ceftazidime/avibactam (CAZ/AVI) in the treatment of carbapenem-resistant Klebsiella pneumonia (CRKP) infection in patients after liver transplantation, and it can provide reference for anti-infection treatment.

    Methods

    All 20 cases with CRKP infection treated by CAZ/AVI after liver transplantation in Beijing Youan hospital from October 2020 to September 2021 were retrospectively analyzed infection indexes, liver and kidney function indexes were compared before and after treatment. Pathogenic bacteria, treatment plan and course, outcome and risk factors were assessed.

    Results

    After liver transplantation, CRKP were detected in 8 cases, mixed infection were detected in 12 cases, among which CRKP was detected in 6 donor preservation fluids. The treatment time was (10.60±7.36) d. All 4 cases were treated with single drug (CAZ/AVI) and 16 cases were treated with combination therapy. The effective rate was 75%. After treatment, the infection indexes in the effective group were those in the ineffective group. Glutaminotransferase, total bilirubin, direct bilirubin in the effective group were lower than those in the ineffective group. Continuous renal replacement therapy (CRRT) was the risk factor for the treatment failure with CAZ/AVI.

    Conclusion

    CAZ/AVI can be used as a candidate choice for CRKP infection after liver transplantation, and CRRT contribute to the treatment failure.

  • Zijun TANG, Jiayu GUO, Jinyan TANG, Xiaohua YING
    World Clinical Drug. 2022, 43(3): 294-299.
    Objective

    According to analysis on the basic characteristics of listed innovative drug, market access and medical insurance access from 2017 to 2020 in China, we provided a reference for the early layout of the follow-up market and medical insurance decision-making.

    Methods

    The chemical innovative drugs and biological drugs listed in China from 2017 to 2020 were selected as the research object, and the differences in drug types, production attributes and evaluation items were analyzed from the aspects of overall situation, disease field and medical insurance access.

    Results

    The number of listed drugs increased steadily in the past four years. Among them, the number of chemical drugs was significantly higher than that of biological drugs, the number of imported drugs was significantly higher than that of domestic drugs, and the number of listed drugs, drugs entering the medical insurance catalogue and innovation review projects in the field of cancer were the largest.

    Conclusion

    In the future, chemical drugs will still occupy the dominant position in the market. Biopharmaceutical technology and domestic innovation ability need to be further improved. In popular areas such as oncology, drugs are more innovative and the access rate of drug medical insurance is also high.

  • Zixuan HE, Wei LI, He ZHU, Sheng HAN
    World Clinical Drug. 2022, 43(3): 300-308.
    Objective

    To evaluate the long-term cost-effectiveness of pioglitazone-metformin versus sitagliptin-metformin in treating Chinese type 2 diabetes mellitus (T2DM) patients, in order to provide reference for rational drug use in clinic.

    Methods

    From the health system perspective, we simulated the quality-adjusted life years (QALYs) of patients over 30 years using the validated CORE diabetes model. Inputs of baseline risk factors were extracted from Chinese epidemiological studies, clinical efficacy and medication cost data were obtained from relevant published resources in China, utility data are model default values. Both outcomes and costs were discounted at 5% annually. In this paper, one-way sensitivity analyses were conducted for discount rates and study durations. Monte Carlo simulation was used for probability sensitivity analysis, and scenario analysis was done for a treatment algorithm without second-line therapy.

    Results

    Basic case analysis indicated that, compared with the sitagliptin-metformin regimen, pioglitazone-metformin regimen lowered the incidence of complication, increased cumulative QALYs by 0.02 (9.49 QALYs vs 9.47 QALYs), and reduced total cost by 7 804 yuan (298 214 yuan vs 306 018 yuan). It was an absolute economic advantage scheme and robust sensitivity analysis results.

    Conclusion

    In the long-term health economic context, compared with sitagliptin-metformin, pioglitazone- metformin is a more economical treatment option with improved QALYs and reduced direct medical costs among Chinese T2DM patients.

  • Kang QIN, Yan DAI, Ke JIN, Jun LI
    World Clinical Drug. 2022, 43(3): 309-312.
  • Caiping GAO, Jing HAN, Runyu ZHOU, Guoxin HUANG, Liping MA, Tao WANG
    World Clinical Drug. 2022, 43(3): 313-318.

    In recent years, flood disasters occur frequently in China. The flood disaster pharmaceutical care emergency support system needs to be developed and improved urgently, so as to effectively ensure the safety of people's lives. This paper reviewed the present situation of the emergency medicines, reserve and pharmaceutical care emergency system in China, and analyzed the characteristics of American pharmaceutical care emergency system from the responsibilities of emergency medicine management organization and forms of national reserves of emergency drugs, so as to provide the reference for the development of actual pharmaceutical emergency guarantee in China.

  • Jie TIAN, Xingrong LI, Jun LIU, Jing WU
    World Clinical Drug. 2022, 43(3): 319-324.

    Chimeric antigen receptor T-cell (CAR-T) therapy, as an innovative therapy, has high clinical value, but its high treatment cost and uncertainty of long-term efficacy bring challenges to medical insurance access. This paper explored the design framework and key elements of CAR-T therapy risk sharing protocol by combing international experience and Chinese practice characteristics, in order to provide reference for Chinese health insurance access policy.

  • Yuhao FU, Xuejiao XUN, Xueru HE, Ran FU, Yanjun CUI, Zhanjun DONG
    World Clinical Drug. 2022, 43(3): 325-330.

    Lung cancer is one of the most common malignant tumors in the world, and it is also the leading cause of cancer-related death. Non-small cell lung cancer (NSCLC) is the main type of lung cancer, and epidermal growth factor receptor (EGFR) gene mutation is a common driving gene for NSCLC. The first and second generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in the treatment of NSCLC with EGFR mutation-positive, but they are prone to drug resistance caused by T790M mutation. Almonertinib is a noval and irreversible third generation EGFR-TKI independently developed in China. It has high selectivity to EGFR sensitization and T790M drug resistance mutation and also has good central nervous system activity and tolerance. In this paper, we reviewed the mechanism of action, pharmacodynamics, pharmacokinetics, clinical research and combination therapy of almonertinib, to provide a reference for clinical application.

  • Qiuhui ZHENG, Mingzhu YANG, Fang SUN, Shuping WANG, Falin WANG
    World Clinical Drug. 2022, 43(3): 331-335.

    Chemotherapy-induced nausea and vomiting (CINV) in cancer patients is common in clinical practice. Traditional Chinese medicine (TCM) has a significant effect on relieving CINV in cancer patients. Based on the special constitution of people in high altitude areas mainly consists of Qi deficiency, phlegm dampness, blood stasis and Qi stagnation. It is proposed that the pathogenesis of CINV in high altitude areas is closely related to the lung, spleen and kidney. The pathogenesis is characterized by Qi deficiency of lung, spleen and kidney, Yang deficiency and blood stasis, accumulation of damp and heat. It is often treated according to the principles of nourishing Qi, warming Yang, removing dampness and promoting blood circulation. In addition, the importance, necessity and the characteristics of medication of the application of invigorating Qi and promoting blood circulation, warming Yang and dampness in CINV for cancer patients in high altitude areas were also analyzed. This paper can provide some clinical reference for TCM treatment of CINV in cancer patients in high-altitude tumor patients.

  • Fang ZHANG, Jie LIU, Taohua SUN, Yan ZHAO
    World Clinical Drug. 2022, 43(3): 336-341.

    Interleukin (IL)-17, includes six subtypes such as IL-17A and IL-17F, plays an important role in the pathogenesis of a variety of immune-mediated diseases. The currently marketed IL-17A inhibitors have good effects on psoriasis, psoriatic arthritis and ankylosing spondylitis. Bimekizumab (UCB4940) is a noval humanized monoclonal immunoglobulin G1 antibody developed by Belgium's Utimes Company, which is designed to selectively bind to specific sites on IL-17A and IL-17F, and simultaneously inhibiting both IL-17A and IL17F, thereby producing a stronger anti-inflammatory effect than inhibiting IL-17A alone. The latest phase Ⅲ clinical study data show that bimekizumab is effective in treating psoriasis and is well tolerated. This article reviewed the pharmacology, pharmacokinetics, clinical efficacy evaluation and safety of bimekizumab.

News